Tom Nolan reviews this week’s research Over the past year we’ve seen various trials that assess vaping as an intervention for smoking cessation. Now we have smoking cessation drugs being studied as interventions to help people stop vaping. Cytisinicline, a plant based alkaloid that targets nicotinic acetylcholine receptors, has been available in the UK since the start of this year. One hundred and sixty non-smokers who use nicotine vapes were randomised to either cytisinicline 3 mg three times a day for 12 weeks or placebo (both groups received behavioural support). Participants were asked to set a quit date seven to 14 days after the start of treatment. Some 31.8% of those in the cytisinicline group, and 15.1% in the placebo group had stopped vaping between nine and 12 weeks (odds ratio, 2.64; 95% CI, 1.06 to 7.10). However, by 16 weeks the gap between the groups had …

中文翻译：

---

帮助成年人戒烟的药物……以及其他研究

汤姆·诺兰回顾了本周的研究 在过去的一年里，我们看到了各种评估电子烟作为戒烟干预措施的试验。现在我们正在研究戒烟药物作为帮助人们停止吸电子烟的干预措施。 Cytisinicline 是一种针对烟碱乙酰胆碱受体的植物生物碱，自今年年初以来已在英国上市。 160 名使用尼古丁电子烟的非吸烟者被随机分配接受金雀花碱 3 毫克，每天 3 次，持续 12 周，或服用安慰剂（两组均接受行为支持）。参与者被要求在治疗开始后 7 至 14 天设定戒烟日期。金雀花碱组中约 31.8% 的人以及安慰剂组中约 15.1% 的人在 9 至 12 周内停止吸电子烟（比值比，2.64；95% CI，1.06 至 7.10）。然而，到 16 周时，两组之间的差距已经……